Background/Purpose ATRT is a rare and aggressive CNS tumor usually presenting in very young children (age less than 5 years). Aggressive treatments have.

Slides:



Advertisements
Similar presentations
A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.
Advertisements

Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.
Pediatric Proton Therapy in the United States: Patterns of Care 2013 Danny Indelicato, MD Andrew Chang, MD.
Management of Ependymomas George Jallo Division of Pediatric Neurosurgery Johns Hopkins University.
Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.
Prostate Cancer Int. 洪 毓 謙. Prostate cancer is the Second leading cause of death from cancer in the United States American male, the lifetime risk of:
Radiation Injury Can Mimic Tumor Progression Following Proton Radiotherapy for Atypical Teratoid Rhabdoid Tumor in Pediatric Patients M Chang 1, F Perez.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Mak KS, 1 Miller RC, 2 Krishnan S, 3 Laperriere N, 4 Micke O, 5 Rutten I, 6 Kadish SP, 7 Ozsahin M, 8 and Mirimanoff RO 8 1 Harvard Medical School, Boston,
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,
Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.
Proton Therapy for Chondrosarcomas of the Skull Base and Cervical Spine: Long-term Experience at Loma Linda University Medical Center D. Y. Kim 2, R. W.
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
“Validation” of the Proposed IASLC/ITMIG Staging Revisions of Thymic Carcinomas Using Data from 287 Patients Yang Zhao; Heng Zhao Division of Thoracic.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Permanent Interstitial Implants Ideal strategy to curatively manage small volume gynecologic malignancies Can deliver high cumulative radiation dose to.
Corresponding author Name; 2015 North Jefferson St; Three-Year Analysis of Urinary Toxicity in Two Prospective Trials.
Phase 2 study of the mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic and neurofibromatosis type.
We retrospectively analyzed 58 patients with ONSM treated between on a dedicated 6 MV stereotactic LINAC. All cases were discussed in a multidisciplinary.
Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
Locatelli F et al. Proc ASH 2013;Abstract 4378.
Jacqulyn Barnes HBCU-UP Program Reading/Writing Segment Summer 2008.
Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.
. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.
C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.
Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung.
T. Hijal MD, A. Al Hamad MD, N. Khalaf, K. Sultanem MD, S. Faria MD and T. Muanza MD McGill University, Department of Radiation Oncology, Montréal, Québec,
Palliative Single 8 Gy Radiotherapy for Symptomatic Aggressive Lymphomas 2666 A -408 Oguchi M, Eba J, Tanaka O, Kozuka T, Murofushi K, Toshiyasu T, Tsurugai.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
1 NDA Clofarabine Cl-F-Ara-A Presented by Martin Cohen, M.D. at the December 01, 2004 meeting of the Oncologic Drugs Advisory Committee meeting.
Increased Local Control of Lung and Liver Tumors Associated with Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response Relationship.
SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
ABSTRACT Purpose This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,
Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.
Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,
Proton Therapy Patterns-of-Care and Early Outcomes for Hodgkin Lymphoma: Results from the Proton Collaborative Group Registry Bradford Hoppe MD, MPH William.
Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis.
PHASE I/II STUDY OF PEGYLATED LIPOSOMAL DOXORUCIN (PLD) AND GEMCITABINE (GEM) IN RECURRENT PLATIN RESISTANT OVARIAN CANCER (OC). A Study of the VWOG.
The POSITIVE study A large international research effort coordinated by International Breast Cancer Study Group (IBCSG) worldwide ALLIANCE for Clinical.
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
Response to chemotherapy
Dosimetry of Alternative Techniques for Accelerated Partial Breast Irradiation Hanh Pham, B.S, CMD, Thanh Nguyen, BS, Christina Henson, MD, Salahuddin.
A Multi-Institutional Dosimetric Evaluation of Proton Versus Photon Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma F. Khan, B. Nguyen,
Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non–Small Cell Lung Cancer  Hann-Hsiang.
Concurrent chemotherapy and intensity modulated radiation therapy in the treatment of anal cancer: A retrospective review from a large academic center 
39/69 hormone replacement 9/69 Cerebrovascular events
An Evaluation of Prostate Volume and Proton Therapy-Related Toxicities
Jesse Conterato, BA&Sc. RSNA 2016
William Hartsell, M.D. Medical Director
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Rectal toxicity for patients treated with proton beam radiation diagnosed with prostate cancer using free rectal water, water filled rectal balloon or.
Bradford Hoppe MD, MPH William Hartsell, MD
Proton Beam Therapy for Liver Cancer is Well Tolerated: Outcomes from the Proton Collaborative Group REG Trial Michael Chuong, M.D.1,2, Smith Apisarnthanarx,
Results: Purpose/Objectives: Methods: Conclusions:
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Average Dose-Volume Ratio
Presentation transcript:

Background/Purpose ATRT is a rare and aggressive CNS tumor usually presenting in very young children (age less than 5 years). Aggressive treatments have improved outcomes. Such strategies have included radiation therapy as studies have demonstrated the benefit of instituting radiation early in the treatment course. However, at such a young age, short and long term radiation toxicities can be devastating. We prospectively enrolled pediatric CNS ATRT patients onto the Proton Collaborative Group registry protocol to evaluate the efficacy and toxicities of proton radiation therapy in this population. Prospective Study on Pediatric Patients with Atypical Teratoid Rhabdoid Tumors (ATRT) of the Central Nervous System (CNS) John Han-Chih Chang 1, Michael Confer 2, Andrew Chang 2, Stewart Goldman 3, Megan Dunn 1, William Hartsell 1. 1 CDH Proton Center, 2 Procure Proton Therapy Center – Oklahoma City, 3 Anne and Robert H. Lurie Children’s Hospital of Chicago. Materials and Methods Twelve consecutive pediatric ATRT patients were treated with at the Central DuPage Hospital Proton Center (n = 7) and the Procure Proton Therapy Center – Oklahoma City (n = 5) between March 2010 – December 2013 utilizing 3D Conformal Proton Therapy. Eight patients were treated per the Dana- Farber Cancer Institute protocol approach, while 4 were treated either on or per Children’s Oncology Group Protocol ACNS Survival data was calculated from the date of diagnosis, while follow up interval was analyzed from last day of radiation therapy. Results All twelve patients were evaluable. They were all 3 years of age or younger (range 4.4 – 37.7 months). Seven patients had gross total resections, while 4 had subtotal resections along with another 1 not documented. All patients received multiagent intensive chemotherapy. Radiation was to local fields for 9 patients, while 3 had craniospinal irradiation. The median follow up was 14.2 months at our last update (range of 1 – 43 months). At last follow up 10 patients were alive without evidence of disease. The other 2 children died of progressive disease at 9.3 and 24.7 months from diagnosis. Median overall survival was 21 months (range of 4.9 – 49.2 months). All patients received the intended course of therapy to 50 – 54 Cobalt Gray Equivalent (CGE). Proton therapy was able to reduce the dose to the cochlea, optic chiasm, hippocampus, and integral whole brain dose relative to historic controls. Only 4 children had grade 3 toxicities during radiation therapy (all were acute nausea, vomiting and anorexia that responded to steroids). Conclusion The initial results on the largest prospective series of CNS ATRT patients treated with proton therapy seem to be favorable. The aggressive treatment regimens utilizing proton beam therapy yield proven efficacy and improved acute toxicity profiles, which is critically important in this young patient population with such an aggressive disease. We look forward to continuing patient treatments and follow up on long term quality of life measures. Figures A & B: Proton Treatment Plan for a 2 year old with Left Frontal ATRT Figures C & D: Proton Treatment Plan for a 2 year old with 4 th Ventricular ATRT A D C B Table 1: Doses to Target Volume and Critical OAR